Research Pipeline

 Home > Research Pipeline

Research Pipeline

This page represents an overview of our research and development efforts.  If you are interested in discussing further information on any of the following projects please contact Mark (mark@topogen.com).
 

Bladder Cancer Diagnostics (BladCan™)

  • Diagnostic Kit for detection of Bladder Cancer in Patients
  • Non-invasive detection using urine sediments
  • IHC based detection
  • SBIR Phase I pending (L. Lignitt, PI)

I.P. Position: provisional filed, non-provisional conversion July 2011
 

Immune Tolerance in Multiple Sclerosis

  • Collaborative project on T-regulatory cell function in Multiple Sclerosis
  • NIH funding (in preparation); PI, Dr. V. De Rosa

I.P. Position: Pending (USPTO Provisional)

 

New Diagnostics for Autoimmune Diseases (Scleroderma)

  • Joint venture, Prius, SRA (Italy)
  • SBIR Phase I pending (Dr. G. Moroncini, PI)

I.P. Position: multiple patents filed (US and PCT)

 

New Diagnostics for Multiple Sclerosis

  • Joint venture, Prius, SRA (Italy)
  • NIH funding in preparation (Dr. G. Moroncini, PI)

I.P. Position: multiple patents filed (US and PCT)

 

Immune Tolerance in Multiple Sclerosis

  • Collaborative project on T-regulatory cell function in Multiple Sclerosis
  • NIH funding in preparation (Dr. V. de Rosa, PI)

I.P. Position: pending (USPTO provisional patent)

 

Anti-cancer Therapeutics with Novel Gold Compounds

  • Innovative anti-topoisomerase I and II targeting drugs based on synthetic structures containing gold
  • Targeted toxicity combining poisoning and catalytic inhibition of DNA topoisomerase pathways
  • Initial screening done by National Cancer Institute demonstrated efficacy in cancer
  • Subsequent confirmation by TopoGEN showing topoisomerase targeting
  • NIH funding (SBIR Phase I) pending

I.P. Position: multiple patends filed in US and internationally
 

Anti-cancer Therapeutic Detection In Vivo (In Vivo Link Kit™)

  • Developed to clearly demonstrate Topoisomerase I and II poisoning in the context of the cell
    • Allows unambiguous demonstration of drug efficacy within tumor cells
  • DR-GFP Repair--we have engineered a HR repair reporter using GFP inside cells that contain an ultra-high affinity site for Topoisomerase II cleavages
    • Quantitative GFP readout allows in vivo screenign for topo active and DNA damaging agents

Operational Status: ongoing CRO activity in the mainstream company facility
I.P. Status: "soft IP" uses proprietary content to protect and cover all IP
SBIR Phase I Grant 2010-2011

 

Custom Drug Screening: Contract Research Organization (CRO)

  • Customized Screening Solutions for Novel Anti-cancer Drugs
  • Specific targets include:
    • Eukaryotic Topoisomerases (Type I, II, III)
    • Prokaryotic Topoisomerases (Gyrase, Topoisomerase IV) in E. Coli and S. Aureus
  • DNA Methyltransferase targets

Operational Status: ongoing, income streaming revenues for company operations
I.P. Position: provisional patent (USPTO) on Solid Phase Screening Systems

 

Research Diagnostics: Kits and Reagents for Research

  • Antibodies
  • DNA Targets
  • Kits
  • Enzymes
  • High throughput screening Solid Phase Systems (patent pending licensed from Univ. Central Florida)
  • In Vivo Screening for anticancer drug action (SBIR Phase I submitted/pending)

Operational Status: ongoing, income streaming revenues for company operation
I.P. Position: provisional patent (USPTO) on Solid Phase Screening Systems